Relocation of the
European Medicines Agency

Dublin

Where the world comes to work
ARROW

Minister Harris briefs EU Ambassadors on Dublin’s bid to host European Medicines Agency

10/05/2017

The Minister for Health, Simon Harris T.D., outlined the Irish Government strategy in support of Dublin’s bid for the relocation of the European Medicines Agency (EMA) from London, following the UK’s decision to exit the EU, at a meeting with EU Member State Ambassadors in Government buildings.

As well as government backing, Dublin’s bid also has the support of organisations including the Health Products Regulatory Authority (HPRA); IDA Ireland; Science Foundation Ireland; the patient-led Irish Platform for Patient Organisations, Science and Industry (IPPOSI); and Dublin Airport operator, the DAA.

Pictured: Dr. Lorraine Nolan (HPRA), Dr. Derick Mitchell (IPPOSI), Simon Harris T.D., Professor Mark Ferguson (SFI), Mr. Tommy Fanning (IDA Ireland).

Minister Simon Harris said:
“The Irish Government is fully committed to supporting the EMA relocation to Dublin. We have a whole of Government approach and our state agencies are putting their weight behind our campaign. We will be engaging our EU partners over the coming months in a comprehensive diplomatic campaign to convince the heads of government across the EU that Dublin is the most logical choice to ensure business continuity and minimum disruption to one of the world’s most important regulatory bodies.”

Lorraine Nolan, Chief Executive of the HPRA said:
“Ireland is a recognised global leader in the life sciences and the HPRA has a strong relationship with the EMA. Our existing contribution to the work of the agency is significant for a country the size of Ireland and we are very well placed to continue providing that regulatory expertise with Dublin as the host city.”

Tommy Fanning, Head of Biopharmaceuticals and Food at IDA Ireland said:
“The Irish Government has identified a choice of easily accessible locations to accommodate all EMA requirements. It is essential that the EMA is provided with a world class office building that suits its specific needs, and the Irish Government is committed to providing relocation support and advice to ensure seamless business continuity in a prime Dublin location. As the home to 9 of the top ten pharmaceutical manufacturers and a centre for world class ICT operations, Ireland has extensive experience in this sector.”

Professor Mark Ferguson, Chief Scientific Advisor to the Government and Director General of Science Foundation Ireland (SFI) said:
“Relocating to Dublin will ensure business continuity at all levels of EMA operations with access to a large pool of highly qualified professionals and a vibrant life sciences community”.

Dr Derick Mitchell, CEO of the Irish Platform for Patient Organisations, Science & Industry (IPPOSI) said:
“A move to Dublin would mean a seamless transition for the EMA mission and culture, ensuring continued protection and involvement of patients and consumers both in Europe and here in Ireland.”

Kevin Toland, Chief Executive of the DAA said:
Dublin is one of the EU’s most efficient airports with average transit times from plane disembarkation to city at 45 minutes. It has proven its ability to cater for a high volume of passengers with almost 28 million in 2016. Dublin, which has flights to more than 185 destinations, is also the only capital city in the EU with US preclearance.

The benefits of Dublin are set out in a dedicated brochure and website. www.emadublin.ie

Back to news